[Randomized trial comparing UFT and FT-207 in the treatment of advanced hepatocellular carcinoma (first report: well controlled study on the patients for whom transcatheter arterial embolization could not be applied) Osaka Research Society for Liver, Gallbladder and Pancreas].

In a randomized trial, Tegafur (FT-207) or Tegafur-Uracil (UFT) was administrated to 76 patients with advanced hepatocellular carcinoma for whom transcatheter arterial embolization could not be applied. Efficacy on the reduction of tumor size, subjective symptoms and clinical laboratory findings were comparable in both groups. However, survival rate in the UFT group was significantly higher than in the FT-207 group in only 3 limited subgroups of patients: with nodular type tumor, with main nodule of less than 5 cm in maximum diameter, and without prior chemotherapy. Incidence of adverse effects were higher in UFT group than FT-207 group, but not significantly.